A systematic review of the published literature on bacterial resistance in Central Africa between 1955 and 2008 was performed. Eighty-three publications from seven countries were retrieved, the majority presenting data on enteric and other Gram-negative pathogens. Despite methodological limitations in many studies, alarming resistance rates are noted in nearly all pathogens. Of special concern are multidrug resistance in Shigella and Salmonella spp. and the emergence of meticillin-resistant Staphylococcus aureus, high-level penicillin-resistant Streptococcus pneumoniae and extended-spectrum ␤-lactamases among Gram-negative pathogens. These findings make clear that the Central African region shares the worldwide trend of increasing antimicrobial resistance and is in urgent need of sound surveillance based on competent and affordable microbiology to provide clear data on antimicrobial resistance. These data could enable redaction of local treatment guidelines and fuel national and regional policies to contain antimicrobial resistance.
Introduction
Developing countries face substantial problems of antimicrobial resistance. Contributing factors include those involving the public (e.g. self-medication), prescriber (e.g. misinformation, absence of diagnostic tools) and dispenser (e.g. over-the-counter use, inadequate storage, use of expired drugs) [1, 2] . Correct knowledge of actual resistance patterns is the cornerstone of successful containment of antimicrobial resistance. Good-quality data are available from more affluent and transitory countries (e.g. in Latin America [3] and Asia [4, 5] ), but there is little information available from many countries in sub-Saharan Africa, especially from the Central African region. Thus, a systematic review was performed to compile the available information on bacterial resistance in this region.
Materials and methods
The region of Central Africa was considered as described in the United Nation's geoscheme [6] , comprising the countries Cameroon, Chad, Gabon, São Tomé e Príncipe, Congo-Brazzaville, Democratic Republic of the Congo (DRC) (formerly Zaire), the Central African Republic (CAR), Angola and Equatorial Guinea. The study focused on bacterial pathogens, excluding Mycobacterium Relevant microorganisms and antibiotics were primarily those listed by the WHO Surveillance Standards. Key organisms included Staphylococcus aureus, Streptococcus pneumoniae, the enteric pathogens (i.e. Campylobacter, Vibrio, Shigella and Salmonella spp.), Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae and Neisseria meningitidis. Antibiotics included the first-line antibiotics [benzyl penicillin, ampicillin and/or amoxicillin, oxacillin, trimethoprim/sulfamethoxazole (SXT), tetracycline, chloramphenicol, erythromycin, clindamycin and nalidixic acid] as well as representatives of the different generations of cephalosporins, aminoglycosides and fluoroquinolones. Unless otherwise stated, intermediate-resistant strains were grouped together with resistant strains. Mean resistance rates for data from different studies combined were calculated by dividing the sum of all resistant organisms (nominator) over the sum of all organisms tested (denominator). The minimum number of isolates per species for separate reporting was set at 10, in line with the European Society of Clinical Microbiology and Infectious Diseases Study Group for Antimicrobial Resistance Surveillance (ESGARS) [8] and the Clinical and Laboratory Standards Institute (CLSI) [9] recommendations.
Results

Overview of study design, study setting and microbiological methods
A total of 173 articles published between 1954 and 2008 were retrieved, of which 83 were eligible for inclusion in the review. The majority of these publications originated from DRC (n = 37, including 3 publications on data from Rwandese and Congolese patients during cross-border epidemics), followed by CAR (n = 15) and Cameroon (n = 14) (Fig. 1) . More than one-half (43/83; 51.8%) of the studies were surveillance studies, the majority of them studying enteric pathogens (30/43; 69.8%) in DRC (21/43; 48.8%). Another large part of the studies (34/83; 41.0%) were retrospective laboratory studies or short-term clinical studies.
Most studies (50/83; 60.2%) were carried out in urban settings. Of the rural studies, nearly three-quarters (18/25; 72.0%) were performed in DCR, mainly on Shigella spp. and other enteric pathogens. The median duration of studies was 16.5 months (range 1-133 months).
Among the studies that mentioned the patients' age groups, there was a predominance of studies on or involving children (40/50; 80.0%). The origin of infection was clearly retrievable in 56 studies, most of which (52/56; 92.9%) described communityacquired infections, and only 4 studies explicitly addressed nosocomial infections [10] [11] [12] [13] . Co-morbidity was stated in only five studies, mainly human immunodeficiency virus (HIV) and sickle cell anaemia [14] [15] [16] [17] [18] .
A research or reference laboratory was involved in 58 (69.9%) of the 83 studies, the vast majority of which addressed Vibrio cholerae and Shigella spp. Faeces were the most frequently studied clinical sample (42/83; 50.6%), followed by blood (19/83; 22.9%) and cerebrospinal fluid (CSF) (18/83; 21.7%).
The methodologies of antibiotic susceptibility testing were described in 71 studies (85.5%), including mainly the disk diffusion method (60/83; 72.3%) and the agar dilution method (17/83; 20.5%). Broth dilution and Etest were performed in four and three studies, respectively. Batch testing with the agar dilution method was mainly used by reference laboratories assessing outbreaks of V. cholerae and Shigella spp. Only 31 (37.3%) of 83 studies mentioned a reference method such as the Kirby-Bauer method (or its modifications) or the methods of the CLSI [19] or the French Society for Microbiology [20] . Use of control stains and participation in external quality programmes were mentioned in only 14 and 3 studies, respectively. Only 5 (6.0%) of 83 studies considered only one sample per patient and per episode as recommended [21] . (Table 1) [10, 17, [22] [23] [24] [25] [26] [27] [28] Resistance data for S. aureus were reported in nine studies, including three surveillance studies and six clinical studies from urban hospitals. Although a wide range of samples (pus, wounds, urine and CSF) was addressed from mixed origins (community, nosocomial), only one study considered blood cultures [24] . Of note is that in some studies panels for susceptibility testing were not in accordance with WHO surveillance standards, e.g. did not contain oxacillin or an equivalent antibiotic [24] .
Resistance rates for different species
Gram-positive bacteria
Staphylococcus aureus
As can be seen in Table 1 , the presence of meticillin-resistant S. aureus (MRSA) was examined in six studies. Kesah et al. [10] surveyed MRSA prevalence in eight African countries, including Cameroon as the only country from Central Africa. They found MRSA in 27 (21.3%) of 127 Cameronese samples. This was among the top three highest prevalence figures in the study, only after Kenya (38/137; 27.7%) and Nigeria (42/142; 29.6%). A recent Congolese study [26] among nasal staphylococcal carriers reported an MRSA prevalence of 63.1%, 66.7% and 23.3% in hospitalised patients, hospital staff and outpatients, respectively. Table 2) [14, 15, 22, [28] [29] [30] [31] [32] [33] [34] [35] Data were found in 11 studies conducted between 1990 and 2008, mainly in urban children. Clinical samples were predominantly from CSF (8/11; 72.7%); one study described blood culture isolates [15] . Another two studies described surveillance in nasopharyngeal isolates from healthy and sick children [31, 32] .
Streptococcus pneumoniae (
Overall, low numbers of isolates were studied (range 7-272; median 34); only 4/11 studies tested more than 50 isolates. Penicillin was tested in eight studies, of which only four distinguished between 'intermediate' and 'high-level' resistance. Although rates of intermediate resistance to penicillin were reported up to 67.0%, high-level resistance remained <6% overall. Notable resistance rates were those for SXT (up to 69%) and chloramphenicol (up to 60%).
Gram-negative bacteria
4.2.1. Shigella spp. [16, [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] Eighteen studies were found, mainly from rural DRC (12/18; 66.7%) and published between 1955 and 2006. Two-thirds reported on outbreak investigations, and Shigella dysenteriae type 1 was the predominant serotype (15/18 studies). Occasionally, samples from blood, CSF or pus were included [16, 49] . Multiresistant Shigella isolates emerged in the late 1970s. A survey from Kinshasa (DRC) in 1964 demonstrated resistance to two or more antibiotics in 10% of 368 strains. In 1979, spread of a clone with plasmid-mediated resistance to ampicillin, chloramphenicol, streptomycin, sulphonamides and tetracycline was noted in Eastern Zaire (now DRC) [37, 41, 47, 48] and 2 years later 75% of the strains showed additional trimethoprim resistance through a newly acquired plasmid. Dysentery treatment consequently shifted to nalidixic acid, to which resistance developed in May 1982, disappearing after the discontinuation of mass treatment with nalidixic acid [43] . Several reports described the large outbreak of S. dysenteriae dysentery among Rwandese refugees after the 1994 civil war [36, 40, 42, 52] , reporting similar patterns of multidrug resistance including nalidixic acid and trimethoprim, leaving the newer fluoroquinolones as a treatment option. Bercion et al. [38] and Cunin et al. [44] described similar outbreaks in CAR and Cameroon, respectively. Even outside the epidemic context, the prevalence of multidrug-resistant strains was found to be >50% in recent reports from Kinshasa (DRC) [49] and Bangui (CAR) [53] . [16, 18, 45, 49, [54] [55] [56] [57] [58] [59] [60] [61] [62] (Table 3) . Thirteen studies between 1973 and 2005 addressed S. Typhi, mainly in urban settings in DRC and Gabon (10/13; 76.9%). Six of them were surveillance studies [45, 49, 54, [60] [61] [62] , of which five were conducted in DRC. Isolates were recovered from blood and faeces. Although mean resistance rates to amoxicillin, chloramphenicol and SXT were relatively low, there was a steeply increasing upward trend towards 50% resistance rates since the mid 1990s. Overall susceptibility for fluoroquinolones remained high. Only a single study [60] tested resistance for nalidixic acid as a predictor for fluoroquinolone resistance: all 37 samples were sensitive. Combined resistance was described in at least three studies. In a paediatric bacteraemia study in the DRC, Kariuki et al. [60] found resistance to five or more first-line antibiotics in >95% of the isolates. [23, 24, 28, 45, 49, 54, 59, [61] [62] [63] [64] [65] [66] ( Table 4 ). The general study characteristics were similar to those reporting on S. Typhi, with five studies also addressing nosocomial infections. High mean resistance rates were noted for ampicillin (63.0%), chloramphenicol (42.9%) and the fluoroquinolones (16.8%).
Salmonella spp. 4.2.2.1. Salmonella enterica serovar Typhi
Non-typhoid Salmonella (NTS)
Resistance to SXT was relatively low (14.6%) and no resistance was noted to cefotaxime. Unlike S .Typhi, there was no clear temporal trend, except for SXT and the fluoroquinolones to which resistance emerged from 1999 onwards.
Multiresistance was reported frequently. In a 1973 study of a hospital outbreak in DRC, Kashemwa et al. [45] noted 24% of all NTS isolates to have combined resistance to ampicillin, streptomycin, kanamycin, tetracycline, chloramphenicol and sulfamethoxazole. Also in DRC, in 1977 Muyembe et al. [62] observed multiresistance in 76% of 1070 NTS isolates, of which >90% were co-resistant to at least five commonly used antibiotics. In a 1993 Congolese bacteraemia study, multiresistance was noted in 30% of all NTS; 90% of isolates were co-resistant to ampicillin, chloramphenicol, tetracycline, streptomycin, sulphonamides, streptomycin and SXT [64] . Similar findings were described in Bangui (CAR) [66] . [40, 42, [67] [68] [69] [70] [71] [72] [73] [74] [75] Eleven reports from nearly all countries in the region were available. Most were published in the second half of the 1990s, often describing outbreaks among refugees, all by V. cholerae O1 El Tor. Three studies from Chad, Cameroon and DRC noted little or no resistance [70, 73, 75] . However, extensive and multidrug resistance was described from outbreaks in DRC (1995-1997) with strains resistant to first-line drugs including ampicillin, tetracycline, doxycycline, SXT, nalidixic acid and chloramphenicol. In the same period, similar findings were reported from neighbouring Angola [67, 72, 74] . Of nine studies testing ampicillin, seven showed high (≥84%) rates of resistance. For tetracycline and chloramphenicol, four of eight studies revealed very high (>90%) resistance rates. Isolates were resistant to sulphonamides or SXT in six and five of eight studies, respectively. (Table 5 ) [23, 24, 25, 44, [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] Most data on E. coli were retrieved from clinical or laboratory archives, predominantly from urine and faeces, and rarely from blood or pus. Two publications focused on enteroaggregative E. coli in children [78, 79] , and Cunin et al. [44] described a dysentery outbreak with E. coli 0157 in Cameroon. Overall, broad ranges of antibiotics were used for susceptibility testing and several inappropriate drugs (e.g. clindamycin, erythromycin, tetracycline and doxycycline) were tested [23, 25] . The reported and mean resistance rates were very high for all commonly used antibiotics but also for amoxicillin/clavulanic acid and first-generation cephalosporins. Resistance remained much lower for aminoglycosides, fluoroquinolones and nitrofurantoin, and no resistance to third-generation cephalosporins was reported by the cited authors with the exception of Gangoue-Pieboji et al. [76] . Data on multiresistance were recorded from DRC and Gabon by Jalaluddin et al. [78] and Burchard and Wolff [25] , respectively. The former described 10 different resistance patterns, with the most frequent pattern being combined resistance to tetracycline, ampicillin, chloramphenicol, streptomycin and chloramphenicol. Similarly, 26.7% of 86 isolates in the latter study combined resistance to ampicillin with doxycycline, SXT and chloramphenicol. Table 6) [11, 23, 24, 25, 33, 76, 80, 81, [83] [84] [85] Eleven authors described resistance patterns in Klebsiella spp. from a variety of samples (blood, urine, respiratory, pus and faeces). Similar to E. coli, the source of information was archived clinical or laboratory data in large urban centres from a heterogeneous group of patients, covering the period 1976-2006. High resistance rates were noted for amoxicillin/clavulanic acid (52.9%), chloramphenicol (43.2%), gentamicin (47.7%) and SXT (80.3%). For fluoroquinolones and third-generation cephalosporins, resistance is emerging (7.4% and 3.3%, respectively). Susceptibility to carbapenems remained preserved. Ndip et al. (Cameroon) [11] and Burchard and Wolff (Gabon) [25] described multiresistance for (combinations of) ampicillin, doxycycline, SXT and chloramphenicol at 77.3% and 33%, respectively.
Vibrio cholerae
Escherichia coli
Klebsiella spp. (
Presence of extended-spectrumˇ-lactamase (ESBL)
Two authors focused on the presence of ESBLs in Gram-negative bacteria [12, 86, 87] . Both used the double-disk method and studied miscellaneous Enterobacteriaceae, mostly E. coli and Klebsiella spp. Frank et al. in Bangui (CAR) [87] described an ESBL prevalence of 4% among 450 Enterobacteriaceae isolates. In addition, nearly 65% of the ESBL-producing isolates showed combined resistance to aminoglycosides, tetracycline and fluoroquinolones. In Cameroon, Gangoué-Pieboji et al. [12] observed the presence of ESBL in 13 (14.3%) of 91 E. coli isolates and in 12 (18.8%) of 64 Klebsiella spp. tested. A large part (47-84%) of these isolates was of nosocomial origin. Most of them carried CTX-M-15 and SVH-12 and to a lesser extent CTX-M-3 and SHV 2a as the responsible gene. (Table 7) [25, 76, 88, 89] Four studies described resistance data from urine, pus and respiratory tract samples and the hospital environment; they included few invasive (blood) samples. At least one study included nosocomial samples [88] . Resistance was not limited to gentamicin and piperacillin but also extended to fluoroquinolones and ceftazidime (15.5% and 32.2% mean resistance rates, respectively). Resistance to carbapenems was looked for in a single study and remained low (6%).
Pseudomonas aeruginosa
Multiresistance to clinically relevant antibiotics was assessed by Ndip et al. in Cameroon [88] , who noted combined resistance to at least two antibiotics in all strains. Multidrug resistance to at least four antibiotics was as frequent as 41.2%. [14, 28, 29, 34, [90] [91] [92] Data between 1968 and 2008 were found, mainly from countries near to the meningitis belt (i.e. Chad, Cameroon). Unlike most Table 6 Antimicrobial resistance rates of Klebsiella spp., Central Africa [11, 23, 24, 25, 33, 76, 80, 81, [83] [84] [85] a . [91, 92] and third-generation cephalosporins (2/61; 3.3%) [29, 92] . [22, 28, 29, 32, 34, 35, 93] and Moraxella catarrhalis [94] Seven studies reported on H. influenzae strains, with the following mean resistance rates: ampicillin 34.3% (68/198) ; thirdgeneration cephalosporins 6.2% (6/97); chloramphenicol 11.6% (23/198); gentamicin 41.3% (19/46) ; and SXT 32.7% (37/113). Screening of respiratory samples from 19 rural Angolan children for the presence of ␤-lactamase in M. catarrhalis revealed a prevalence of 89.5%.
Gram-negative cocci
Neisseria meningitidis
Miscellaneous
Haemophilus influenzae
Discussion and conclusion
In this study we reviewed published data on bacterial resistance in Central Africa. There are several limitations to this study. First, the exploration of data was problematic. For logistical reasons we did not search the 'grey' literature. Owing to historical collaboration and institutional and private networks, some countries such as DRC and Cameroon were most represented; for Equatorial Guinea and São Tomé e Príncipe, no usable data were found. Second, at present we did not consider agents of mycobacterial and sexually transmitted infections.
Regarding the retrieved studies, several issues regarding epidemiological and microbiological methods must be mentioned. First, it should be noted that few studies were designed as prospective surveillance studies. Furthermore, many studies performed susceptibility testing on only a fraction of isolates recovered, and few studies mentioned selection of a single strain per patient and episode. Enteric pathogens (Shigella, Salmonella, Vibrio spp.) were far more represented than the other key pathogens. Only a few reports [10, 13] addressed genuine nosocomial and/or invasive isolates, which are notorious for their antimicrobial resistance even in developing countries [95] . On the other hand, urine, respiratory and wound samples from clinical studies might include a selection of difficult-to-treat infections and hence possibly present a bias toward resistant strains [96] . With regard to microbiological methods, few studies mentioned application of quality assurance in identification and susceptibility testing, and quantitative susceptibility data (e.g. MICs or inhibition diameters) were only rarely available. Likewise, distinction between intermediate and highlevel resistance in case of S. pneumoniae was not always reported, and in several studies panels of antibiotics selected for testing were heterogeneous (making comparisons difficult) or even inappropriate.
Despite the limitations, several interesting observations can be made. The studies on Shigella and Vibrio spp. give a good impression on the evolution of their epidemiology and resistance patterns, particularly in the eastern part of DRC. The resistance patterns of Shigella spp. are in line with those found in the neighbouring countries of Rwanda and Burundi, which have historically been investigated together with DRC [97] [98] [99] [100] [101] . Given the fact that these pathogens often act in outbreaks among weakened people, these very extensive resistance patterns urge for very tight surveillance and frequently updated treatment policies in case of outbreaks.
Resistance data on the other pathogens were much more scarce and heterogeneous and displayed wide ranges in resistance rates. Nevertheless, worrying trends are to be noted, especially among Gram-negative enteric organisms. The actual multiresistance patterns of NTS and the emerging resistance trends among S. Typhi isolates are of concern, as many of the widely used cheap firstline antibiotics are no longer active for the treatment of these endemic organisms. In particular, emerging fluoroquinolone resistance is of concern. With regard to other Enterobacteriaceae and non-fermentative organisms such as P. aeruginosa, only estimations of antimicrobial resistance patterns can be given, but it is clear that multiresistant isolates including those with ESBL are present.
In Gram-positive pathogens data are even more scarce and heterogeneous. The real prevalence of colonising and invasive MRSA infections in this region remains unclear. The problem is underscreened and possibly underestimated.
Penicillin resistance in S. pneumoniae was more consistently tested but was rarely expressed as intermediate or high-level resistance despite its relevance for future empirical antibiotic guidelines. High-level resistance was seen rarely but an increase in intermediate-level resistance was noted.
The present data should be a matter of concern and increased awareness, especially in view of their entanglement with other major health problems highly prevalent in the Central African region such as HIV/acquired immune deficiency syndrome (AIDS), tuberculosis, malnutrition and malaria. Bacterial infections often coincide or complicate the course of other health problems. Shifts in antibiotic use for one infection can jeopardise treatment options for another [102] .
Therefore, there is need for genuine and integrated surveillance. Bacteriology as a diagnostic tool in individual patient management is probably not cost effective, but cohort-based surveys [103] studying a limited set of key pathogens in selected locations, with limited duration and repeated over time, may provide valuable information for the redaction and adaptation of standard treatment guidelines. Prerequisites for any type of laboratory surveillance are the implementation of quality-assured procedures and the availability of culture media, reagents and control strains of correct quality and at a reasonable cost. Most important, competent and dedicated laboratory staff collaborating closely with the medical and nursing staff are needed. Partnerships with laboratories in resource-rich countries [104] may be helpful for local capacity building through teaching, providing feedback and performing more expensive or technically complex investigations on selected strains.
In conclusion, although the present data only give a glimpse of the antimicrobial resistance rates of bacteria in Central Africa, it is clear that this region shares the worldwide trend of increasing antimicrobial resistance. Sound surveillance based on competent and affordable microbiology is required to provide clear data on antimicrobial resistance, which in turn can enable redaction of local treatment guidelines and fuel national and regional policies to contain antimicrobial resistance.
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